NCT02155543 - A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions

Healthy Volunteers

Interventions

DRUG

AGN-223575 Formulation A

One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.

DRUG

AGN-223575 Formulation B

One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.

DRUG

AGN-223575 Formulation C

One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.

DRUG

AGN-223575 Vehicle

One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.

Trial Locations (1)

Unknown

Newport Beach